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Background: The rationale for commissioning community pulmonary rehabilitation programmes is based on
evidence from randomised clinical trials. However, there are a number of reasons why similar programmes might
be less effective outside the environment of a clinical trial. These include a less highly selected patient group and
less control over the fidelity of intervention delivery. The main objective of this study was therefore to test the
hypothesis that the real-world programme would have similar outcomes to an intervention delivered in the context
of a clinical trial.
Methods: As part of the evaluation of an innovative community-based pulmonary rehabilitation programme
(“BreathingSpace”), clinical and quality of life measures were collected before and after delivery of a rehabilitation
programme. Baseline characteristics of participants and the change in symptoms and quality of life after the
BreathingSpace programme were compared to measures collected in the community-based arm of a separate
randomised trial of pulmonary rehabilitation.
Results: Despite differences between the BreathingSpace participants and research participants in clinical status at
baseline, patient reported symptoms and quality of life measures were similar. Improvements in both symptoms
and quality of life were of the same order of magnitude despite the different contexts, setting and scale of the two
intervention programmes. Whilst 73% (326/448) of those considered suitable for community rehabilitation in the
trial and 80% (393/491) assessed as suitable for the BreathingSpace programme agreed to participate, less than half
of participants completed rehabilitation, whether in a research or “real world” setting ( 47% and 45% respectively).
Conclusion: The before-after changes in outcomes seen in a “real world” community rehabilitation programme
are similar in magnitude to those seen in the intervention arm of a clinical trial. However suboptimal uptake and
high dropout rates from rehabilitation amongst eligible participants occurs in both clinical trials and community
based programmes and must be addressed if the benefits of rehabilitation for people with chronic lung disease
are to be maximised.
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The rationale for commissioning community pulmonary
rehabilitation programmes is based on the results of
randomised controlled trials (RCTs) in which rehabilita-
tion has been shown to be effective and cost-effective in
increasing exercise tolerance, reducing symptoms, improv-
ing quality of life and reducing hospital admissions [1-3].
Randomised controlled trials provide the “gold stand-
ard” for assessing effectiveness due to their high internal
validity [4]. Only an RCT can properly allow for all
confounders, both known and unknown, and a properly
delivered RCT will minimise important sources of bias.
This is in contrast to observational studies in which
selection bias is often problematic, and in which it is
very difficult to adjust for unknown confounders [5].
Guidance from the National Institute of Health and
Clinical Excellence (NICE) and similar bodies on the
effectiveness and cost-effectiveness of both drugs and
complex interventions, including rehabilitation, is there-
fore based largely on the results of RCTs where these
results are available [6].
However, it is not necessarily true that a randomised
controlled trial has high external validity, in the sense
that we cannot automatically expect to see the same ef-
fect size (or the same cost-effectiveness) when we deliver
the intervention in a routine setting as was observed in
the trial. There are a number of possible reasons for this:
adherence to the intervention protocol may be less strict
in the routine setting, and inclusion criteria for partici-
pants are likely to be more pragmatic. A trial typically
attracts dedicated funding, whereas a programme that is
delivered as part of usual health service provision must
compete for scarce resources, particularly the time and
commitment of clinicians and therapists. Lastly, the very
nature of being observed in a trial can result in different
behaviour by both patients and clinicians and therefore po-
tentially a different outcome (the “Hawthorne effect”) [7].
In this study we compared the outcomes of pulmonary
rehabilitation delivered in a randomised controlled clin-
ical trial, with a similar programme delivered in a rou-
tine clinical setting. Our null hypothesis was that there
was no difference in the change in outcome before and
after the intervention in the clinical trial, compared with
the before-after change in the routine clinical setting. A
secondary aim was to evaluate uptake and dropout rates
in both the BreathingSpace and randomised trial setting.
Methods
We used a retrospective cohort study design and com-
pared baseline characteristics and before-after change in
outcomes between two groups: the community-based pul-
monary rehabilitation intervention arm of the Waterhouse
et al. randomised controlled trial that took place in the city
of Sheffield, South Yorkshire, between 2004 and 2005 [8]and the group of patients who undertook pulmonary re-
habilitation in the “BreathingSpace” community rehabilita-
tion programme in the neighbouring town of Rotherham,
South Yorkshire, between 2007 and 2008 [9]. Ethics ap-
proval for the BreathingSpace Evaluation and for the trial
were granted by the Rotherham NHS Local Research Eth-
ics Committee and South Sheffield NHS Local Research
Ethics Committee respectively [8,9].Interventions
Both the trial and the BreathingSpace rehabilitation
programmes were delivered in community venues and
consisted of a total of 12 or 16 sessions delivered by sup-
port workers who were trained and supervised by expe-
rienced therapists. Classes were delivered over six weeks
in the trial and over eight weeks in BreathingSpace.
BreathingSpace had relatively broad inclusion criteria for
participation, and included non-COPD patients, whilst
the trial intervention was limited to patients with a spe-
cific diagnosis of COPD and MRC grade 3 (or worse)
dyspnoea. Table 1 summarises the characteristics of the
rehabilitation programmes delivered in the trial and in
BreathingSpace and their inclusion criteria. More details
are available [8,9]. Overall the main differences between
the two programmes are those that might typically be
found when comparing a randomised trial intervention
and a community programme outside the context of a
trial, in that although the trial was designed as a “prag-
matic” trial and the trial protocol and report stresses that
“access to the sessions was designed to follow usual clin-
ical practice, reflecting ‘real life’ conditions” [8], the inter-
vention did have more restrictive inclusion criteria (MRC
severity grade of 3 or greater) and a more standardised
intervention (“Programmes were identical in each venue,
with exercises following a protocol and a core syllabus for
each of the educational aspects” [8]).Data collection and analysis
We obtained data for the intervention arm of the ran-
domised controlled trial from the published trial report [8]
and for BreathingSpace from an audit and evaluation pro-
ject [9]. This included data on patient eligibility, recruit-
ment and retention rates, baseline characteristics and
post-rehabilitation follow-up data. Post-rehabilitation out-
comes were measured immediately after completion of
the rehabilitation programmes in both settings to maxi-
mise retention and minimise missing data at that point.
Since the trial was restricted to patients with MRC breath-
lessness grades from 3–5 only and BreathingSpace re-
cruited patients at all grades, to ensure comparability we
restricted our primary analysis to patients from both
programmes with MRC breathlessness grades from 3–5.
We repeated the analyses including all patients to
Table 1 Intervention protocols for randomised trial and
BreathingSpace
Randomised trial
intervention protocol
BreathingSpace
community rehabilitation
programme
Duration of
programme
Twice weekly 2 hour classes
for 6 weeks (total 12 hours)
Twice weekly 90 minute
classes for 8 weeks (total
12 hours)
Delivery of
programme
Delivered by physiotherapist
and support worker,
assessments performed by
research team
Delivered by trained
support workers supervised
by physiotherapist or
occupational therapist
Content of
programme
1 hour of review, warm-up,
exercise and cool-down;
1 hour for education;
participants being
encouraged to exercise
between formal classes.
Exercise diary kept between
sessions and individualised
exercise booklet provided at
the end of the course.
1 hour of warm-up, exercise
and cool-down; 30 minutes
for education; participants
being encouraged to
exercise and keep an
exercise diary between
formal classes.
Inclusion/
exclusion
criteria
Diagnosis of COPD by
respiratory physician, using
GOLD guidelines
Diagnosed respiratory
condition confirmed with
spirometry;
Medical Research Council
(MRC) grade 3 or worse
dyspnoea despite optimal
medical care
Experiencing breathlessness
in day to day life despite
optimal respiratory
medication
Clinically stable at least
4 weeks before
commencing rehabilitation.
No cardiac event in the past
3 months and any known
cardiac condition well
controlled and stable.
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severe grades was likely to have an impact of overall
effectiveness.
Whilst the trial cohort included all those who were
randomised to the community rehabilitation progra-
mme and attended for follow up data collection, the
BreathingSpace cohort included all those who had
follow up data collected following the rehabilitation
programme irrespective of their attendance for the
programme, but excluding those who did not take up an
offer of rehabilitation. We compared the following base-
line characteristics: mean age, proportion male partici-
pants, mean body mass index, mean FEV1 (Forced
expiratory volume in 1 second) mean FEV1 as a propor-
tion of predicted, mean FVC (Forced Vital Capacity ie
the volume of air that can forcibly be blown out after
full inspiration), mean FVC as a proportion of pre-
dicted, mean relaxed vital capacity, mean FEV1/FVC
and proportion in each MRC breathlessness grade [10].
We also compared baseline mean CRQ (Chronic
Respiratory Disease Questionnaire) symptom severity
[11], mean domain specific SF-36v2 (measuring quality
of life defined in terms of physical functioning, role-
physical, bodily pain, general health, vitality, social function-
ing, role-emotional, mental health, physical componentsummary, mental component summary), and overall SF-
36v2 score (an summary measure of quality of life across
all domains [12] and mean EQ-5D-3 L (a standardised
measure of health status developed by the EuroQol Group
which provides a simple, generic measure of health) [13].
These measures have all been widely used to evaluate self-
reported outcomes of pulmonary rehabilitation [14] as
they measure both symptoms in four domains (CRQ do-
mains with range 1–7 for both individual and mean do-
main responses) and quality of life (domains of SF-36
with range 0–100; SF-6D and EQ-5D-3 L with range 0
(death) to 1 (perfect/full health)). Minimal clinically im-
portant differences for these outcome measures were
defined, as for the randomised trial [8] as 0.5 points for
CRQ domains, 5 points for SF-36 dimensions, 0.04
points for SF-6D score and 0.07 points for EQ-5D score.
We compared the following outcome measures, where
outcomes were defined in terms of the difference in each
measure before and after the rehabilitation intervention:
CRQ symptoms (dyspnoea, fatigue, emotion, mastery), SF-
36v2 domains, SF-36v2 overall score), and EQ-5D-3 L.
The primary objective was to evaluate whether the be-
fore/after mean difference was different between the two
settings. We used the individual patient data from the
community rehabilitation arm of the trial and the clin-
ical outcomes data collected by the BreathingSpace
programme patients to calculate mean before and after
differences.
For baseline characteristics we tested for differences be-
tween the trial and BreathingSpace using unpaired t-tests
for continuous measures, and a Chi-square test for mea-
sures expressed as proportions. For outcomes we tested
for differences in the before-after differences using un-
paired t-tests. We considered differences between the trial
and BreathingSpace statistically significant if p < 0.05.
We also report the difference in mean before-after
differences in outcomes between the trial community
rehabilitation intervention arm and BreathingSpace,
along with 95% confidence intervals.
Results
Recruitment and retention
In the clinical trial, out of 1041 patients assessed, 448
(43%) were considered suitable for the programme and
326 of those (73%) gave informed consent to random-
isation. Of the 162 randomised to community re7ha-
bilitation, 111 (69%) attended the initial assessment of
whom 76 had data at baseline and immediately post-
rehabilitation. Subsequently, these participants attended
about two-thirds of sessions (mean 62.53% (sd 7.3%);
range 0-100%). Less than half (47%) of those ran-
domised to community rehabilitation, who all had met
eligibility criteria and given informed consent to parti-
cipation, both attended and completed the programme.
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643 patients attending for assessment, 491 (76%) were
assessed as suitable for rehabilitation and 393 (80%) of
those agreed to attend. Audit data from the rehabilita-
tion programme subsequently showed that only 45%
(608/1355) of rehabilitation attendees attended more
than 13 sessions and 37% (314/1355) attended less
than eight sessions [15]. Only 451 rehabilitation partici-
pants provided symptom and quality of life data at base-
line (Table 2) and the tables show the number of patients
who provided data for specific outcome measures at both
baseline (Tables 3 and 4) and post-rehabilitation (Tables 5
and 6). The different numbers of participants on which
the results are based in Tables 2 to 6 (varying from 71 to
111 for the trial and from 451 to 308 for BreathingSpace)
reflect differences in the completeness of data with respect
to the different outcomes measured.
Baseline characteristics
There were no significant differences in either the mean
age or the gender distribution between the trial interven-
tion arm and BreathingSpace (Table 2). The communityTable 2 Baseline clinical characteristics (at pre-rehabilitation
Randomised trial –
community setting
intervention group
n Mean SD Min Max
Age (years) 111 68.7 8.3 49 86
Body mass index (kg/m2) 111 25.4 5.6 14.0 44.0
FEV1 (litres) 111 1.1 0.4 0.3 2.6
Actual FEV1 as a proportion of predicted
FEV1 (%)
111 45.1 16.3 16.8 89.8
FVC (litres) 111 2.7 0.9 1.2 5.3
Actual FVC as a proportion of predicted FVC
(%)
111 86.7 19.3 50.8 137.
Relaxed vital capacity (litres) 111 2.7 0.9 1.4 5.1
FEV1/FVC 111 0.4 0.1 0.2 1.0
n %
Gender
Female 49 44
Male 62 56
Total 111 100
MRC breathlessness grade
1 - -
2 - -
3 38 34
4 37 33
5 36 32
Total 111 100participants had higher body mass indices but had signi-
ficantly better lung function. This is consistent with the
smaller proportion at MRC Grade 5 in the BreathingSpace
(10% versus 32%) and is due at least in part to the different
inclusion criteria of the trial and BreathingSpace. Brea-
thingSpace accepts patients with MRC grades 1 and 2
breathlessness, whereas these participants were excluded
from the trial. Despite these differences, patient reported
symptoms and quality of life measures were similar in the
two populations (Tables 3 and 4).
Respiratory symptoms and quality of life outcomes
Pre-rehabilitation and post-rehabilitation outcomes were
collected for 329 BreathingSpace participants and 80 trial
participants (Tables 5 and 6). Both groups improved with
similar changes seen in the trial and BreathingSpace. The
differences in mean before-after differences in outcomes
between the trial community rehabilitation intervention
arm and BreathingSpace were all small, and smaller than
the clinically important difference. Confidence intervals
for the differences in differences contained zero (the null
value) for all outcomes except the Physical Functioningassessment)
BreathingSpace – all
participants
n Mean SD Min Max P-value for difference between
groups
451 69.7 8.9 45 92 0.3
421 27.5 6.5 12.5 66.2 0.001*
416 1.2 0.5 0.3 3.0 0.03*
417 48.3 16.6 15.0 117.0 0.07
415 2.4 0.8 0.9 6.5 0.002*
5 412 79.4 18.1 28.0 136.0 <0.001*
398 2.5 0.8 0.7 6.1 0.04*
412 0.5 0.1 0.2 0.9 <0.001*
n %
219 49 0.5
231 51
450 100
8 2 <0.001*
68 16
169 40
132 32
41 10
418 100
Table 3 Baseline self-reported symptoms and quality of life measures (at pre-rehabilitation assessment) including only
participants MRC grade ≥3
Randomised trial – community setting
intervention group
BreathingSpace –
participants MRC ≥3
n Mean SD n Mean SD P-value for difference in means
CRQ symptoms
Dyspnoea 75 3.2 0.9 329 2.9 1.0 0.002*
Fatigue 75 3.3 1.2 329 3.4 1.3 0.73
Emotion 75 4.4 1.3 329 4.4 1.4 0.92
Mastery 75 4.3 1.4 329 4.5 1.4 0.40
SF-36v2 domains
Physical functioning 75 32.0 20.3 335 31.8 23.4 0.95
Role-physical 76 36.6 22.0 333 36.7 27.4 0.98
Bodily pain 74 58.2 27.9 313 54.4 29.7 0.30
General health 74 35.6 18.7 304 33.1 19.5 0.30
Vitality 75 38.7 18.6 306 37.7 21.2 0.68
Social functioning 76 49.7 30.8 313 52.6 33.0 0.47
Role-emotional 76 58.1 29.8 304 56.3 34.0 0.65
Mental health 76 65.1 21.5 310 66.4 20.5 0.63
PCS (Physical component summary) 71 32.2 7.4 291 31.2 9.7 0.32
MCS (Mental component summary) 71 42.3 12.2 291 43.7 13.1 0.38
SF-6D 71 0.61 0.11 291 0.59 0.12 0.10
EQ-5D-3 L 76 0.56 0.27 291 0.50 0.21 0.09
* significant at 5% level.
Table 4 Baseline self-reported symptoms and quality of life measures (at pre-rehabilitation assessment) – including
BreathingSpace patients MRC grade < 3
Randomised trial – community setting
intervention group
BreathingSpace – all
participants
n Mean SD n Mean SD P-value for difference in means
CRQ symptoms
Dyspnoea 75 3.2 0.9 481 2.9 1.1 0.02*
Fatigue 75 3.3 1.2 481 3.5 1.3 0.2
Emotion 75 4.4 1.3 481 4.5 1.3 0.6
Mastery 75 4.3 1.4 481 4.5 1.4 0.2
SF-36v2 domains
Physical functioning 75 32.0 20.3 443 32.0 23.2 1.0
Role-physical 76 36.6 22.0 442 36.7 26.7 1.0
Bodily pain 74 58.2 27.9 413 53.6 29.2 0.2
General health 74 35.6 18.7 401 33.4 20.0 0.4
Vitality 75 38.7 18.6 404 37.9 20.8 0.7
Social functioning 76 49.7 30.8 413 53.1 32.7 0.4
Role-emotional 76 58.1 29.8 404 55.6 34.1 0.5
Mental health 76 65.1 21.5 408 66.4 20.5 0.6
PCS (Physical component summary) 71 32.2 7.4 385 31.0 9.7 0.3
MCS (Mental component summary) 71 42.3 12.2 385 43.7 13.1 0.4
SF-6D 71 0.61 0.11 381 0.60 0.12 0.6
EQ-5D-3 L 76 0.56 0.27 385 0.53 0.23 0.4
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Table 5 Impact of rehabilitation programme on respiratory symptoms and quality of life - including only participants
MRC > =3
Randomised trial –
community setting
intervention group
BreathingSpace – participants MRC > =
3Mean after-before difference
n Mean before-
after difference
SD n Mean before-
after difference
SD Difference in mean
before-after differences
(95% CI)
P-value for difference in
mean before-after
differences
CRQ symptoms
Dyspnoea 74 0.29 1.18 329 0.55 1.20 0.26 (−0.04, 0.56) 0.09
Fatigue 75 0.58 1.12 329 0.51 1.21 −0.07 (−0.36, 0.21) 0.61
Emotion 74 0.39 0.98 329 0.34 1.15 −0.05 (−0.31, 0.21) 0.70
Mastery 75 0.36 1.08 329 0.27 1.24 −0.09 (−0.37, 0.19) 0.53
SF-36v2
domains
Physical
functioning
79 0.87 17.6 333 5.81 20.4 4.94 (0.36, 9.53) 0.03*
Role-physical 79 8.25 24.6 331 7.30 27.0 −0.95 (−7.27, 5.36) 0.77
Bodily pain 78 1.29 25.8 277 2.93 26.3 1.64 (−5.07, 8.35) 0.63
General health 77 3.93 15.7 263 3.17 17.0 −0.76 (−4.94, 3.42) 0.72
Vitality 79 8.15 16.8 269 7.59 21.4 −0.55 (−5.18, 4.08) 0.81
Social
functioning
80 12.7 29.5 277 8.35 32.7 −4.31 (−12.04, 3.42) 0.27
Role-emotional 79 5.17 31.0 268 7.91 34.8 2.74 (−5.44, 10.93) 0.51
Mental health 80 5.81 15.7 274 4.76 19.5 −1.05 (−5.31, 3.20) 0.62
PCS (Physical
component
summary)
73 0.98 6.49 249 1.31 7.76 0.33 (−1.48, 2.13) 0.72
MCS (Mental
component
summary)
73 5.38 10.4 249 3.95 12.8 −1.43 (−4.35, 1.49) 0.34
SF-6D 72 0.014 0.10 245 0.030 0.11 0.016 (−0.010, 0.043) 0.23
EQ-5D-3 L 80 0.066 0.28 249 0.044 0.15 −0.022 (−0.086, 0.042) 0.51
* significant at 5% level.
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more than those in the trial (Table 5). However, this find-
ing should be viewed with caution given that the overall
Physical component summary improvement and overall
SF-36 improvements were similar between groups. Re-
peating the analyses including 152 Breathing Space pa-
tients with MRC Grades 1–2 (a total of 481 patients) in
the Breathing Space cohort gave similar results (Table 6).
Discussion
The primary objective was to evaluate whether the be-
fore/after mean differences in outcomes seen at Brea-
thingSpace were different to those reported in the
intervention arm of the trial. Despite some differences
between BreathingSpace participants and research par-
ticipants in clinical status at baseline, patient reported
symptoms and quality of life measures were similar in
the two populations. Improvements in both symptoms
and quality of life were of the same order of magnitudein both programmes despite the different contexts, set-
ting and scale of the two intervention programmes. In
particular, the inclusion of patients with less clinically se-
vere disease (less than MRC Grade 3) does not appear to
have reduced the overall effectiveness, a finding consis-
tent with previous evaluations [16]. In both the clinical
trial and the larger scale programme, a high proportion
of those originally assessed, and who might have poten-
tially benefited, either did not start or did not complete
the programme. This suggests that the barriers to par-
ticipation and completion of rehabilitation are not only
due to the additional constraints of involvement in a
trial but also occur in “real world” non-research settings.
There is no clear consensus or evidence base to support
any particular threshold for regarding attendance as ad-
equate before an individual can be said to have received
an adequate “dose” of rehabilitation in this context. The
relationship between attendance and outcomes will be
confounded by other factors that will influence both
Table 6 Impact of rehabilitation programme on respiratory symptoms and quality of life– including BreathingSpace
patients MRC grade 1-2
Randomised trial –
community setting
intervention group
BreathingSpace – all
participants
n Mean before-
after difference
SD n Mean before-
after difference
SD Difference in mean before-
after differences (95% CI)
P-value for difference in
mean before-after differences
CRQ symptoms
Dyspnoea 74 0.29 1.18 481 0.61 1.25 0.32 (0.03, 0.62) 0.03*
Fatigue 75 0.58 1.12 481 0.48 1.22 −0.10 (−0.38, 0.18) 0.31
Emotion 74 0.39 0.98 481 0.36 1.15 −0.03 (−0.27, 0.22) 0.79
Mastery 75 0.36 1.08 481 0.32 1.20 −0.04 (−0.31, 0.23) 0.86
SF-36v2 domains
Physical
functioning
79 0.87 17.6 438 5.47 20.1 4.61 (0.16, 9.06) 0.08
Role-physical 79 8.25 24.6 437 7.36 26.6 −0.9 (−7.04, 5.24) 0.57
Bodily pain 78 1.29 25.8 356 2.55 26.3 1.25 (−5.30, 7.80) 0.71
General health 77 3.93 15.7 337 3.29 16.5 −0.64 (−4.68, 3.40) 0.78
Vitality 79 8.15 16.8 345 6.75 20.5 −1.4 (−5.82, 3.03) 0.42
Social functioning 80 12.7 29.5 356 7.97 31.7 −4.69 (−12.16, 2.79) 0.11
Role-emotional 79 5.17 31.0 346 7.77 32.9 2.6 (−5.26, 10.46) 0.38
Mental health 80 5.81 15.7 351 4.65 18.7 −1.16 (−5.23, 2.92) 0.48
PCS (Physical
component
summary)
73 0.98 6.49 317 1.11 7.5 0.13 (−1.61, 1.87) 0.84
MCS (Mental
component
summary)
73 5.38 10.4 317 3.78 12.1 −1.59 (−4.39, 1.20) 0.24
SF-6D 72 0.014 0.10 308 0.029 0.11 0.015 (−0.011, 0.040) 0.30
EQ-5D-3 L 80 0.066 0.28 317 0.039 0.14 −0.027 (−0.090, 0.036) 0.42
* significant at 5% level.
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status. We suspect that poor attendance could be caus-
ally associated with both poorer health (participants not
well enough to attend) and with better health (partici-
pants feeling well enough to take up other normal activ-
ities and responsibilities and therefore choosing not to
attend) so interpreting whether (and why) better atten-
dance might predict better or worse outcomes requires
further research.
This analysis is based on a comparison of a group of
patients recruited to a clinical trial of community-based
pulmonary rehabilitation and a group of patients receiv-
ing community-based pulmonary rehabilitation in clini-
cal practice. The first group were exposed to pulmonary
rehabilitation as part of a Sheffield based randomised trial,
funded by the Health Technology Appraisal Programme
(NIHR HTA programme). The second group were ex-
posed to rehabilitation as part of a large community
programme based in the purpose-built “BreathingSpace”
facility in the neighbouring town of Rotherham. The con-
tent and delivery of both programmes was based on asimilar interpretation of the evidence base for COPD re-
habilitation programmes at that time [1]. This provides a
unique opportunity to compare the impact of rehabilita-
tion seen in a controlled trial with the impact achieved in
a routine community setting. However, whilst we have as-
sumed that as both groups were identified from geograph-
ically adjacent populations and both identified as suitable
for community-based pulmonary rehabilitation, they rep-
resent similar populations, there is always the potential for
patients included in research studies being selected to be
different from the patients that take up the intervention in
clinical practice.
The other main weaknesses of this analysis are those
associated with any secondary analysis, in that the data
available for analysis are limited to those that were col-
lected for the original analyses. Potentially useful missing
information included measures of baseline differences
such as the presence or absence of co-morbidities,
smoking status and information on other relevant clin-
ical measures such as walking distance and health care
service use. However from the data that were collected,
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lar populations who received similar programmes.
Some studies that have compared the results of ran-
domised trials and observational studies have found that
they generate similar results [17]. Although a number of
studies have considered the rationale for expecting differ-
ences between trials and observational studies, none to date
have considered the empirical evidence for a difference in
the clinical effectiveness of a specific complex intervention
such as pulmonary rehabilitation, when replicated in a non-
research setting.
Other authors have shown that the effect sizes ob-
served in randomised trials can be quite different to
those observed in non-randomised studies of the same
intervention [18]. This is not surprising given the prob-
lems of internal validity (i.e. bias and confounding) that
are inherent in non-randomised studies. Our question
is somewhat different and relates to the external valid-
ity of a randomised trial. Can we expect to see the same
outcomes in the routine clinical setting that we saw in
the trial? Based on the results we present for pulmon-
ary rehabilitation we conclude that, outcomes similar
to those achieved in clinical trials can be achieved in
the “real world”.Conclusions
We conclude that the before-after changes in out-
comes seen in a “real world” community rehabilitation
programme are similar in magnitude to those seen in
the intervention arm of a clinical trial. However, the rela-
tively low participation and completion rates that are ob-
served in the context of trials, and which might be
thought to be specific to the trial setting (due for example
to the requirements of an onerous consent process) also
exist in “real world” programmes. The barriers to partici-
pation in any pulmonary rehabilitation programme, trial
or otherwise, that are indicated by these findings need to
be addressed if the potential benefits of rehabilitation for a
larger number of people with chronic lung disease are to
be maximised.Competing interests
AG, GS, OR and GB were involved in the delivery of BreathingSpace
programmes. RL was principal investigator for the NIHR-funded pulmonary
rehabilitation trial and has received payment for Board membership
(Novartis, GSK) and received grants and payment or expenses for
presentations and meetings (GSK, Novartis, Boehringer, Nycomed, Astra
Zeneca).Authors’ contributions
EG, MS, AG and GB conceived the study, and participated in its design and
coordination. MS and MH carried out the statistical analyses and EG wrote
the first draft of the manuscript. RL, OR, GB and GM also provided
information about the interventions and data collection process in both
settings. All authors contributed to the interpretation of the findings and to
drafting the manuscript. All authors read and approved the final manuscript.Acknowledgements
The RCT was funded by the Health Technology Assessment programme and
the BreathingSpace Evaluation by NHS Rotherham. This analysis was funded
by the COPD Theme programme of the National Institute for Health
Research Collaboration for Leadership in Applied Health Research and Care
for South Yorkshire (NIHR CLAHRC SY). The views and opinions expressed are
those of the authors, and not necessarily those of the NHS, the NIHR or the
Department of Health. NIHR CLAHRC SY would also like to acknowledge the
participation and resources of our partner organisations. Further details can
be found at www.clahrc-sy.nihr.ac.uk.
Author details
1ScHARR, University of Sheffield, Regent Court, 30 Regent St, Sheffield S1
4DA, UK. 2NIHR CLAHRC South Yorkshire, NHS Rotherham CCG, Rotherham,
UK. 3Respiratory Medicine, Rotherham General Hospital, Rotherham, UK.
4Sheffield Teaching Hospital NHS Trust, Sheffield, UK.
Received: 17 April 2013 Accepted: 5 August 2013
Published: 13 August 2013References
1. Lacasse Y, Goldstein R, Lasserson TJ, Martin S: Pulmonary rehabilitation for
chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006,
4(4):CD003793.
2. Puhan MA, Gimeno-Santos E, Scharplatz M, Troosters T, Walters EH, Steurer
J: Pulmonary rehabilitation following exacerbations of chronic
obstructive pulmonary disease. Cochrane Database Syst Rev 2011, 10:
CD005305.
3. Griffiths TL, Phillips CJ, Davies S, et al: Cost effectiveness of an outpatient
multidisciplinary pulmonary rehabilitation programme. Thorax 2001,
56:779–784.
4. Moher D, Hopewell S, Schulz KF, et al: CONSORT 2010 explanation and
elaboration: updated guidelines for reporting parallel group randomised
trials. BMJ 2010, 340:c869.
5. Pocock SJ, Collier TJ, Dandreo KJ, et al: Issues in the reporting of
epidemiological studies: a survey of recent practice. BMJ 2004, 329:883.
6. National Clinical Guideline Centre 2010: Chronic obstructive pulmonary
disease: management of chronic obstructive pulmonary disease in adults in
primary and secondary care. Available from http://guidance.nice.org.uk/
CG101/Guidance/pdf/English (2010, accessed 1st May 2012).
7. Franke RH, Kaul JD: The Hawthorne experiments: first statistical
interpretation. Am Sociol Rev 1978, 43:623–643.
8. Waterhouse JC, Walters SJ, Oluboyede Y, et al: A randomised 2 × 2 trial of
community versus hospital pulmonary rehabilitation for chronic
obstructive pulmonary disease followed by telephone or conventional
follow-up. Health Technol Assess 2010, 14(6):1–164.
9. NHS Rotherham and ScHARR (University of Sheffield) BreathingSpace
Research and Evaluation Advisory Group: Final Evaluation Report 2009.
http://www.rotherham.nhs.uk/clinicians/evaluation.htm (Accessed 3rd
August 2012).
10. Fletcher CM, Elmes PC, Fairbairn MB, et al: The significance of respiratory
symptoms and the diagnosis of chronic bronchitis in a working
population. Br Med J 1959, 2:257–266.
11. Williams J, Singh S, Sewell L, Guyatt G, Morgan M: Development of a self-
reported Chronic Respiratory Questionnaire (CRQ-SR). Thorax 2001,
56:954–959.
12. Ware JE Jr, Kosinski M, Bjorner JB, Turner-Bowker DM, Gandek B, Maruish
ME: User’s Manual for the SF-36v2 Health Survey. 2nd edition. Lincoln, RI:
Quality Metric Incorporated; 2007.
13. The EuroQol Group: EuroQol-a new facility for the measurement of
health-related quality of life. Health Policy 1990, 16:199–208.
14. Stahl E, Lindberg A, Jansson SA, Ronmark E, Svensson K, Andersson F, et al:
Health-related quality of life is related to COPD disease severity. Health
Qual Life Outcomes 2005, 3:56.
15. Reddington O, Telford A, Stott V, South G: Large-Scale Community
Pulmonary Rehabilitation: more than a question of numbers. Thorax
2009, 64(suppl IV):A98.
16. Evans RA, Singh SJ, Collier R, Williams JE, Morgan MD: Pulmonary
rehabilitation is successful for COPD irrespective of MRC dyspnoea
grade. Respir Med 2009, 103:1070–1075.
Goyder et al. BMC Medical Research Methodology 2013, 13:103 Page 9 of 9
http://www.biomedcentral.com/1471-2288/13/10317. Shrier I, Boivin JF, Steele RJ, Platt RW, Furlan A, Kakuma R, et al: Should
meta-analyses of interventions include observational studies in addition
to randomized controlled trials? A critical examination of underlying
principles. Am J Epidemiol 2007, 166:1203–1209.
18. Deeks JJ, Dinnes J, D’Amico R, Kunst H, Gibson A, Cummins E, et al:
Evaluating nonrandomised intervention studies. Health Technol Assess
2003, 7:iii–173.
doi:10.1186/1471-2288-13-103
Cite this article as: Goyder et al.: Is a large scale community programme
as effective as a community rehabilitation programme delivered in the
setting of a clinical trial?. BMC Medical Research Methodology 2013 13:103.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
